AC6 mRNA expression showed the same pattern, as seen in Fig 7B (fold change from control; C: 1.03 ± 0.11; CKD: 2.30 ± 0.49; CKD + T: 0.98 ± 0.35; T: 0.96 ± 0.38), while V2 receptor mRNA expression was not significantly modified by CKD or Tolvaptan administration (Fig 7C fold change from control; C: 0.85 ± 0.20; CKD: 0.90 ± 0.43; CKD + T: 0.65 ± 0.26; T: 1.05 ± 0.37). The gene discussed is ADCY6; the disease is chronic kidney disease.